Lundbeck's anti-drinking med Selincro nabs final U.K. funding; Endo pays $25 million-plus for testosterone gel Natesto;

> The U.K.'s cost-effectiveness gatekeepers gave their final OK for Lundbeck's anti-alcoholism drug Selincro (nalmefene). Report

> Fingerpaint, a Saratoga Springs, NY-based agency, snapped up a Phoenix-based shop, Olson Communications, in a bid to build out a West Coast presence to attract more pharma clients based there. Report

> Leo Pharma recruited Barbara Osborne to head up its U.S. regional office as president and CEO; she'll also join the Denmark-based company's global executive team. Release

> Endo Pharmaceuticals ($ENDP) snapped up the rights to a testosterone nasal gel, Natesto, from Trimel BioPharma; the drug was approved by the FDA in May. Release

> Novartis ($NVS) regained its online domain name in Indonesia from a local squatter that was using the domain illegally. Report

> Ireland will require pharma companies to disclose payments to doctors and other healthcare professionals beginning Jan. 1; gifts were banned earlier this year. Report

And Finally... Novartis said the FDA has extended its review of the company's new multiple myeloma drug bortezomib. Release

Suggested Articles

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.

Sanofi’s chief digital officer isn’t surprised to see CDOs popping up across Big Pharma. But they have to earn their keep, he says.

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.